Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.38 |
| ▸ | KHK | P50053 | 3/20 | 0.35 |
| ▸ | ABL1 | P00519 | 9/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25316582 | 1.00 | PDE3B (0.38) | PDE3BPDE3AKHKABL1SOS1 | |
| SCHEMBL25318053 | 0.84 | PDE3B (0.37) | PDE3BPDE3AKHKABL1SOS1 | |
| SCHEMBL20354191 | 0.81 | ACACB (0.40) | ABL1SOS1OPRK1 | |
| SCHEMBL26040948 | 0.79 | OPRK1 (0.36) | ABL1OPRK1 | |
| SCHEMBL21546427 | 0.77 | OPRK1 (0.39) | ABL1OPRK1 | |
| SCHEMBL31698630 | 0.77 | AAK1 (0.35) | PDE3BPDE3AKHKABL1SOS1 | |
| SCHEMBL26028942 | 0.77 | ABL1 (0.37) | PDE3BPDE3AKHKABL1CNR2 | |
| SCHEMBL31698905 | 0.75 | ABL1 (0.35) | PDE3BPDE3AKHKABL1CNR2 | |
| SCHEMBL31698510 | 0.75 | ABL1 (0.37) | PDE3BPDE3AKHKABL1CNR2 | |
| SCHEMBL26028944 | 0.75 | PDK2 (0.38) | PDE3BPDE3AKHKABL1SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | PDE3B 2853/4885PDE3A 3458/4885KHK 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.